Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study.

Abstract Objectives: To estimate the rate of progression from seroconversion to symptomatic disease in adults infected with HIV-1, and to establish whether the background level of signs and symptoms commonly associated with HIV-1 in uninfected controls are likely to affect progression rates. Design: Longitudinal, prospective cohort study of people infected with HIV-1 and randomly selected subjects negative for HIV-1 antibodies identified during population studies. Setting: Study clinic with basic medical care in rural Uganda. Subjects: 275 patients infected with HIV-1 (107 prevalent cases and 168 incident cases) and 246 controls negative for HIV-1 antibodies. Main outcome measures: Signs and symptoms of HIV disease, as determined by stages 2 and 3 of the World Health Organization clinical staging system. Results: The median time from seroconversion to WHO stage 2 was 25.4 months and to stage 3 was 45.5 months. 43% of the participants infected with HIV-1 had signs or symptoms by two years after seroconversion. The most common clinical conditions used to define progression of disease were weight loss, mucocutaneous manifestations, bacterial infections, chronic fever, and chronic diarrhoea. Although the rates of these conditions (apart from minor weight loss) were significantly higher in the participants infected with HIV-1, they were also relatively frequent in the control group. Herpes zoster, oral candidiasis, and pulmonary tuberculosis were not common events in the control group and therefore were more indicative of infection with HIV-1. Conclusions: Disease progression associated with infection with HIV-1 seems to be rapid in rural Uganda. This is most likely due to the high prevalence of conditions in the general population that could be taken as symptoms and signs of infection with HIV-1. What is already known on this topic The few studies that have reported time from seroconversion to HIV-1 symptomatic disease in poor countries suggest that this interval is shorter than in rich countries What this study adds Progression from seroconversion to symptomatic disease seems to be rapid in rural Africa The apparent rapid disease progression in rural Africa is most likely to be due to the high prevalence of what could be taken as symptoms and signs of HIV-1 in the general population

[1]  A Wilkins,et al.  Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV‐1 or HIV‐2 infection , 1992, AIDS.

[2]  R. Brettle,et al.  Clinical features of early HIV in the Edinburgh City Hospital cohort , 1996, International journal of STD & AIDS.

[3]  W. Miller,et al.  Diagnosis and screening of HIV/AIDS using clinical criteria in Tanzanian adults. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[4]  N. Nagelkerke,et al.  Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. , 1995, The Journal of infectious diseases.

[5]  J. Stephenson,et al.  Disease progression and survival in HIV‐1‐infected Africans in London , 1998, AIDS.

[6]  J. Pape,et al.  HIV infection in Haiti: natural history and disease progression , 2000, AIDS.

[7]  N. Nagelkerke,et al.  Transition dynamics of HIV disease in a cohort of African prostitutes: a Markov model approach. , 1990, AIDS.

[8]  A. Phillips,et al.  Progression of HIV disease in a haemophilic cohort followed for 11 years and the effect of treatment. , 1991, BMJ.

[9]  S. Buchbinder,et al.  The spectrum of medical conditions and symptoms before acquired immunodeficiency syndrome in homosexual and bisexual men infected with the human immunodeficiency virus. , 1995, American journal of epidemiology.

[10]  T. Quinn,et al.  Seroconversion rate, mortality, and clinical manifestations associated with the receipt of a human immunodeficiency virus-infected blood transfusion in Kinshasa, Zaire. , 1991, Journal of Infectious Diseases.

[11]  A. Kamali,et al.  Seven-year trends in HIV-1 infection rates, and changes in sexual behaviour, among adults in rural Uganda , 2000, AIDS.

[12]  Peter Piot,et al.  Joint United Nations Program on HIV/AIDS (UNAIDS) , 1997 .

[13]  P. Flegg Barnett Christie Lecture (1993). The natural history of HIV infection: a study in Edinburgh drug users. , 1994, The Journal of infection.

[14]  J. Kaewkungwal,et al.  Disease progression and survival with human immunodeficiency virus type 1 subtype E infection among female sex workers in Thailand. , 2000, The Journal of infectious diseases.

[15]  I. Thior,et al.  Reduced rate of disease development after HIV-2 infection as compared to HIV-1. , 1994, Science.

[16]  S. Hulley,et al.  Predictors of Mortality among HIV-infected Women in Kigali, Rwanda , 1992, Annals of Internal Medicine.

[17]  J. Whitworth,et al.  An HIV‐1 natural history cohort and survival times in rural Uganda , 1997, AIDS.

[18]  N. French,et al.  Immunologic and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced disease. , 1999, Journal of acquired immune deficiency syndromes.

[19]  R. Salamon,et al.  Four years of natural history of HIV-1 infection in african women: a prospective cohort study in Kigali (Rwanda), 1988-1993. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[20]  β2-microglobulin as a predictor of death in HIV‐infected women from Kigali, Rwanda , 1994, AIDS.

[21]  T. Quinn,et al.  Human immunodeficiency virus infection among employees in an African hospital. , 1988, The New England journal of medicine.

[22]  T. Quinn,et al.  NATURAL HISTORY OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN ZAIRE , 1986, The Lancet.

[23]  H. Joller,et al.  Antiretroviral treatment monitoring with an improved HIV‐1 p24 antigen test: an inexpensive alternative to tests for viral RNA , 2001, Journal of medical virology.

[24]  N. French,et al.  Immunologic and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced disease. , 1999 .